		·		Tarana and a same a same and a same					
FORM F (REV. 7		90 (Modified) U.S. PATENT AND TRADEM	ATTORNEY'S DOCKET NUMBER						
	TR	ANSMITTAL LETTER 1	PB60743USW						
		ESIGNATED/ELECTE	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)						
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371									
INTERNATIONAL APPLICATION NO.			INTERNATIONAL FILING DATE 2/10/05	PRIORITY DATE CLAIMED					
TIT1 F		CT/EP2005/001540	2/12/04						
	TITLE OF INVENTION BENZOFURAN AND BEZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR								
	DISEASE								
A DDL	IC A A IT	E(C) FOR BOJEOUIS	·						
		Γ(S) FOR DO/EO/US , et al.							
IIAK	LING	, et al.							
Analia			s Designated/Elected Office (DO/EO/US) the	following items and other information:					
Applic	_	erewith submits to the United State	s Designated/Elected Office (DO/EO/OS) the	ionowing items and other information.					
1.	$\boxtimes$		ms concerning a submission under 35 U.S.C.						
2.			ENT submission of items concerning a submis						
3.	×	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.							
4.	$\boxtimes$	The US has been elected (Article 31).							
5.	$\boxtimes$	A copy of the International Application as filed (35 U.S.C. 371 (c)(2))							
		a. 📋 is attached hereto (required only if not communicated by the International Bureau).							
		b. 🗵 has been communicated by the International Bureau.							
		c. 🔲 is not required, as the application was filed in the United States Receiving Office (RO/US).							
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).							
		a. 🗌 is attached hereto.							
		b.  has been previously submitted under 35 U.S.C. 154(d)(4).							
7.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))							
		a.   are attached hereto (required only if not communicated by the International Bureau).							
		b. 🔲 have been communicated by the International Bureau.							
		c.  have not been made; however, the time limit for making such amendments has NOT expired.							
		d.  have not been made and will not be made.							
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9.	$\boxtimes$	An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).							
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).							
11.		A copy of the International Preliminary Examination Report (PCT/IPEA/409).							
12.	$\boxtimes$	A copy of the International Search Report (PCT/ISA/210).							
Ite	ems 1	3 to 23 below concern documen	t(s) or information included:						
13.	$\boxtimes$	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
15.	$\boxtimes$	A FIRST preliminary amendment.							
16.		A SECOND or SUBSEQUENT preliminary amendment.							
17.		A substitute specification.							
18.		A power of attorney and/or change of address letter.							
19,		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.							
20.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
21.		A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).							
22.		Express Mail Label No.							

Under the Paperwork	Reduction Act of 1995,	no persons a	l are required to respond to	J.S. P	Appro atent and Tradema lection of Information	PT oved for use through 3/31 ark Office; U.S. DEPART on unless it displays a vali	O-1390 (Rev. 07-2005 /2007. OMB 0651-0021 MENT OF COMMERCE d OMB control number	
U.S. APPLICATION NO (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.						ATTORNEY'S DOCKET NUMBER		
		100	PCT/EP20	05/0	01540	PB60743	SUSW	
23. Other iter	ns or information:							
PCT Pub	lication Coverpage							
PCT Req	uest							
i I								
}								
						CALCULATIONS	PTO USE	
	g fees have been sub ational fee				\$300			
	ation fee (37 CFR 1.4					- 5500.0		
If the written opin	ion prepared by ISA/	US or the ii	nternational preliminar	y exa		\$ \$200.0	0	
		-	provisions of PCT Arti		\$0 \$200			
	fee (37 CFR 1.492(b							
			ional preliminary exan visions of PCT Article			Ļ		
			on the international ap			\$ \$400.0	0	
International Sea	rch Report prepared	by an ISA (	other than the US and IB	provi	ided to the			
		•	<u></u>					
	L OF 24, 25 and 2					\$ \$900.0	0	
Additional fe sequence listing in an in The fee is \$2	e for specification an ting in compliance wi electronic medium) (3 250 for each addition							
Total Sheets	Extra Sheets f	Number of each additional 50 or RATE fraction thereof (round up to a whole						
44 - 100 =	0 /50 =		0		× \$250.00	\$ \$0.0	0	
Surcharge of \$13 declaration after	0.00 for furnishing ar	ny of the se ement of the	earch fee, examination ne national stage (37 (	fee, CFR	or the oath or 1.492(h)).	\$		
CLAIMS	NUMBER FILE	ILED NUMBER EXTRA		RATE				
Total claims	21 -	20 =	1	X	\$50.00	\$ \$50.0	0	
Independent clair	ns 1 -	3 =	0	x	\$200.00	\$ \$0.0	0	
MULTIPLE DEPE	ENDENT CLAIMS (if	applicable)		+	\$360.00	\$ \$0.0	0	
<u></u>			AL OF ABOVE CA			\$ \$950.0	0	
☐ Applicant cla	iims small entity stati	us. See 37	CFR 1.27. Fees abov	e are	reduced by	\$ \$0.0	0	
		\$ \$950.0	0					
	f \$130.00 for furnishined priority date (37 C	\$ \$0.00						
THE CAINEST CIAIN	ca priority date (37 C	\$ \$950.00						
	the enclosed assign an appropriate cover	\$ \$0.00						
TOTAL FEES ENCLOSED =						\$ \$950.0	0	
						Amount to be	\$	
						Amount to be	\s	

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a.		A check in the amount of \$	to cover the above fees is enclosed.						
b.	×	Please charge my Deposit Account No.  A duplicate copy of this sheet is enclosed.	07-1392	in the amount of \$	\$950.00	to cover the above fees.			
C.	$\boxtimes$	The Commissioner is hereby authorized to combine to Deposit Account No. 07-1392	Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment eposit Account No. <u>07-1392</u> . A duplicate copy of this sheet is enclosed.						
d.		Fees are to be charged to a credit card. <b>WARNING</b> : Information on this form may become public. <b>Credit card</b> Information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status									
SEND ALL CORRESPONDENCE TO:									
Customer Number				SIGNATUR John L. I	RE Lemanowicz	3			
				NAME	NAME				
	0.	23347		37,380 REGISTRA DATE	ATION NUMBE	iR			